NCT01170052WithdrawnPhase 1
Phase I/II Study With Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-hodgkin's Lymphoma (NHL) Not Eligible for High Dose Chemotherapy and Autologous/Allogeneic Stem Cell Transplantation
Charite University, Berlin, Germany6 sites in 1 country20 target enrollmentStarted: May 1, 2010Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Withdrawn
- Enrollment
- 20
- Locations
- 6
- Primary Endpoint
- Phase I: Dose-finding
Study Overview
Brief Summary
The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose chemotherapy and autologous/allogeneic stem cell transplantation.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 18 years or older
- •Mantle Cell Lymphoma according to REAL/WHO classification
- •First or second relapse or alternatively progression during therapy. Previous use of Bendamustine is permitted, if the patient has reached at least partial remission and progression occured more than 6 months after therapy. Previous high dose chemotherapy with auto-SCT is permitted, if the patient has reached at least partial remission and progression occured more than 12 months after therapy.
- •Patients must not be eligible for high dose chemotherapy with auto-SCT or allo-SCT.
- •Adequate bone marrow function (hemoglobin > 9g/dl, platelet count >100/nL, absolute neutrophil count >1,5 /nL)
- •WHO/ECOG Performance Status 0-2
- •Measurable disease (two perpendicular diameters by either physical or radiological examination)
- •Life expectancy ≥ 3 weeks
- •Written informed consent
Exclusion Criteria
- •Prior treatment with any m-TOR Inhibitor
- •Unstable or severe uncontrolled medical condition (e.g. severe congestive heart failure, myocardial infarction within the past 6 months, severe, uncontrolled arterial hypertension, renal insufficiency requiring hemodialysis, severe pulmonary disease, severe diabetes)
- •Abnormal liver function: transaminases or total bilirubin > 2 x upper limit of normal (ULN)
- •Abnormal renal function: serum creatinine > 2 x upper limit of normal
- •Previous malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix.
- •Concurrent treatment with strong inhibitors of CYP3A4 and/or inducers of CYP3A4
- •Pregnant or breastfeeding women (negative pregnancy test not older than 7 days is required for women of fertile age). Men and women of child-bearing potential must agree to use adequate contraception (i.e. failure rate < 1% p.a. )
- •Major surgery within 4 weeks before study entry; minor procedures (e.g. Implantation i.v. port catheter, Lymphnode biopsy) within 1 week before study entry
- •Previous therapy with any investigational agents within 28 days before study entry
- •Concomitant immunotherapy (e.g. Rituximab) or Chemotherapy other than Bendamustine. Use of systemic steroids should be documented and the Principal Investigator be informed.
- •Central nervous system (CNS) lymphomatous involvement
- •HIV positivity
- •Current or chronic hepatitis B or hepatitis C infection
- •Severe psychiatric illness or Individuals that are placed in an institution due to a magisterial or judiciary command.
- •Inability to comply with study requirements
Outcomes
Primary Outcomes
Phase I: Dose-finding
Time Frame: 6 months
Is the combination of temsirolimus alongside with bendamustine at the suggested dose feasible or are dose reductions necessary. Number of dose reductions or delays of therapy due to hematologic toxicities (CTCAE) or other adverse events according to protocoll.
Phase II: Response Rate (Overall response rate, complete and partial response)
Time Frame: 6 months
What is the response rate of a therapy with temsirolimus and bendamustine.
Secondary Outcomes
- Progression free survival(2 years)
- Safety and Tolerability of Temsirolimus and Bendamustine Combination Therapy(2 years)
Investigators
Study Sites (6)
Loading locations...
Similar Trials
Completed
Phase 2
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell LymphomaDiffuse Large B-Cell LymphomaLymphoma, Diffuse Large-CellDiffuse Large-Cell LymphomaLymphomaNCT01234467UNC Lineberger Comprehensive Cancer Center23
Terminated
Phase 1
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple MyelomaMultiple MyelomaNCT01484626Loyola University3
Completed
Phase 2
A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's LymphomaIndolent Non-follicularNon-Hodgkin's LymphomaNCT01929265Fondazione Italiana Linfomi - ETS73
Completed
Phase 1
Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African AdultsHIV-1-infectionNCT04173819International AIDS Vaccine Initiative225
Completed
Phase 1
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04742101Institut de Recherches Internationales Servier57